Core Scientific Reports Q2 2026 Financial Results with Investor Presentation

Details and Timing of Q2 2026 Financial Disclosure

On July 28, 2026, Core Scientific filed its Q2 2026 financial results with the Securities and Exchange Commission via a current report approximately one month after the quarter ended on June 30, 2026. The disclosure package included a press release and a company presentation, providing investors with comprehensive insights into the company’s operational and financial status during this timeframe.

Filed under Item 2.02 Results of Operations and Financial Condition, this report serves as Core Scientific’s standard quarterly earnings disclosure, ensuring timely market access to the results while adhering to federal securities regulations applicable to NASDAQ-listed companies.

Complex Capital Structure and NASDAQ Listings

Core Scientific’s capital structure includes multiple securities traded on NASDAQ: common stock (CORZ), warrants exercisable at $6.81 (CORZW), and warrants exercisable at $0.01 (CORZZ). This multi-class setup offers investors diverse ways to engage with the company’s equity and reflects its history of corporate reorganizations and financing rounds.

The differing warrant exercise prices indicate financing events at varying valuation points. Warrants with a nominal $0.01 exercise price likely originated from earlier equity financings when the company’s valuation was lower, granting holders rights to acquire shares at favorable terms and potential upside exposure.

Delaware Incorporation and Regulatory Compliance

Incorporated in Delaware with principal offices in Dover, Delaware, Core Scientific holds SEC File Number 001-40046 and IRS Employer Identification Number 86-1243837. Delaware’s robust corporate law environment and specialized Court of Chancery make it a preferred jurisdiction for publicly traded companies.

The company confirmed it does not qualify as an emerging growth company under Securities Act Rule 405 or Exchange Act Rule 12b-2, meaning it complies with full financial reporting standards without extended transition periods for new accounting rules, reflecting its established market presence.

Press Release and Presentation as Primary Disclosure Materials

The current report incorporates by reference a press release and company presentation both dated July 28, 2026, filed as exhibits. These documents contain the detailed financial and operational data for Q2 2026, ensuring all investors receive simultaneous access to material information via SEC Edgar rather than selective channels.

Investors seeking granular financial metrics, management insights, operational highlights, or forward-looking statements should consult these exhibits, as the current report itself does not include specific figures. This layered disclosure approach is consistent with regulatory practices, using the report as the formal filing and exhibits for detailed content.

Regulation FD Compliance and Disclosure Procedures

Core Scientific also invoked Item 7.01 (Regulation FD Disclosure) alongside Item 2.02, ensuring material information was disseminated fairly to all investors simultaneously. Filing via an 8-K form under Regulation FD prevents selective early access to earnings data.

The filing clarifies that information in Items 2.02 and 7.01, including exhibits, is furnished rather than filed, meaning it is not automatically incorporated by reference into other Securities Act filings. This distinction provides regulatory clarity regarding the treatment of earnings disclosures.

Certification by Chief Legal Officer

Todd M. DuChene, Core Scientific’s Chief Legal Officer and Chief Administrative Officer, signed the current report, certifying compliance with Securities Exchange Act Sections 13 or 15(d). His dual role indicates a streamlined governance structure, and his signature ensures accountability for the accuracy and timeliness of the filing.

This certification mechanism is a key component of post-Sarbanes-Oxley regulations designed to uphold financial reporting integrity by holding executives personally responsible for disclosures.

Industry Context: Cryptocurrency Mining and Infrastructure

Operating in the cryptocurrency mining sector, Core Scientific faces a volatile environment influenced by fluctuating digital asset prices, regulatory changes, and capital-intensive operations requiring stable energy supplies. The company’s multi-warrant capital structure reflects the dynamic fundraising environment typical of this industry.

The Q2 2026 results provide investors with insights into Core Scientific’s operational performance amid these sector-specific challenges, including bitcoin price volatility, mining hardware efficiency, and regulatory developments impacting profitability.

Interactive XBRL Data Filing Enhances Transparency

Core Scientific submitted Inline XBRL interactive data files as Exhibit 104 embedded within the filing. This machine-readable format facilitates automated analysis by market data providers and investors, improving accessibility and comparability of the company’s financial information.

This filing complies with SEC mandates requiring structured financial data submissions, supporting more efficient capital markets through rapid aggregation and evaluation of corporate disclosures.

Information Not Included in Current Report

The current report does not disclose specific revenue, earnings per share, net income or loss, balance sheet details, cash flow data, or operational statistics for Q2 2026. These key financial metrics are available only in the attached press release and presentation.

Additionally, the filing excludes forward-looking statements, management guidance, risk discussions, or detailed operational commentary, which are typically presented in earnings press releases. The current report primarily serves as the regulatory vehicle for timely public disclosure of Core Scientific’s quarterly results.